CytomX Therapeutics (CTMX) EBIT Growth (3y) (2017 - 2026)

CytomX Therapeutics (CTMX) EBIT Growth (3y) (2017 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 16.96%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 38.78%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -12.10%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 69.02%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 CytomX Therapeutics 590.32 Mn 243.61 Mn - -51.54%

Historic Data

Download Data
DateValue
Mar 31, 2026 -51.54%
Dec 31, 2025 -43.22%
Sep 30, 2025 19.04%
Jun 30, 2025 65.02%
Mar 31, 2025 39.34%
Dec 31, 2024 35.84%
Sep 30, 2024 28.71%
Jun 30, 2024 31.85%
Mar 31, 2024 35.69%
Dec 31, 2023 70.69%
Sep 30, 2023 28.54%
Jun 30, 2023 49.34%
Mar 31, 2023 -0.97%
Dec 31, 2022 48.09%
Sep 30, 2022 -4.93%
Jun 30, 2022 1.27%
Mar 31, 2022 -24.62%
Dec 31, 2021 -10.58%
Sep 30, 2021 -10.23%
Jun 30, 2021 -26.28%